Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$55.2B
62M shares
52-week range
$510.06 – $934.62
98% from low
Exchange
NASDAQ
ADRC
Borrow rate
0.26%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $24.6M | $78.5M | $41.2M | $497.3M | $410.7M | $1.23B | $2.19B | $4.15B |
| Cost of revenue | $0 | $0 | $0 | $580.5M | $29.4M | $117.8M | $227.3M | $450.7M |
| Gross profit | $24.6M | $78.5M | $41.2M | $497.3M | $381.3M | $1.11B | $1.96B | $3.70B |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 92.8% | 90.4% | 89.6% | 89.1% |
| R&D | $95.6M | $220.8M | $370.5M | $580.5M | $663.4M | $859.5M | $983.4M | $1.36B |
| Operating income | −$93.6M | −$198.9M | −$477.6M | −$348.7M | −$720.3M | −$425.0M | −$21.7M | $1.05B |
| EBITDA | −$93.1M | −$173.4M | −$601.0M | −$392.8M | −$622.8M | −$192.3M | $105.2M | $1.31B |
| Net income | −$76.2M | −$181.2M | −$608.5M | −$407.6M | −$709.6M | −$295.1M | $833.0M | $1.29B |
| Net margin | -310.2% | -231.0% | -1475.3% | -82.0% | -172.8% | -24.1% | 38.0% | 31.1% |
| EPS (diluted) | -2.12 | -4.69 | -13.40 | -7.99 | -13.05 | -5.16 | 12.78 | 19.63 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $6.0B | $26.43 | $23.29–$29.75 | 13 |
| 2027 | $7.3B | $35.79 | $28.84–$41.63 | 13 |
| 2028 | $8.6B | $44.47 | $41.53–$51.38 | 9 |
| 2029 | $9.9B | $53.90 | $50.35–$62.28 | 11 |
Forward consensus · source: Financial Modeling Prep
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
www.argenx.comNo one on the platform currently holds ARGX.
| Institution | Shares | Reported |
|---|---|---|
| Bridgewater Associatesas of 2026-03-31 | 1,214 | $886.5K |
No one on the platform has traded ARGX yet.
| $54.4B |
| — |
| CAHCardinal Health, Inc. | $237.82 | +0.68% | $55.7B | — |
| EWEdwards Lifesciences Corporation | $89.93 | -1.37% | $51.8B | — |
Source: Financial Modeling Prep · peers by sector/industry
$ALNY 's share price & valuation has dropped so meaningfully since Thanksgiving, we now include ALNY in our non-BP trackers. Analysts forecast ALNY to generate slightly more revenues over the next 5 years as $ARGX , albeit at slightly lower gross margins due to ALNY's royalty obligation to $SNY , yet ARGX's enterprise value is 36% higher. Analysts forecast both bio's 10 year revenues to be within 3%. The attached graph visualizes how analysts believe both have virtally identical revenue profiles yet because of the disconnect in valuation, ALNY trades at meaningfully lower multiples. We're only sharing an observation. This is not investment advice. There may be very good reasons for the disconnect. If anyone can share a perspective, it would be genuinely appreciated. $XBI $IBB
View on StockTwits ↗Raymond James reiterated $DNTH Strong Buy; $125 $SNY $ARGX JNJ IMVT - ROIV RNAC KYTX VRTX AZN Here's what Raymond James said: https://x.com/Quantumup1/status/2065519020451708994?s=20
View on StockTwits ↗https://marketbeat.com/a/8709865/ $ARGX argenx Eyes More VYVGART Growth as Pipeline Catalysts Near
View on StockTwits ↗$TGTX +11% on a real catalyst, not a low-float squeeze. Subcutaneous BRIUMVI hit 82% MCID in myasthenia gravis Phase 1 — and they jumped straight to a registration-directed Phase 2. A whole new indication beyond MS just opened up. Stock's already sitting on the $48 Street target, so consensus hasn't priced the MG shot at all. And the "high debt" knock is backwards: TGTX holds more cash than debt. I read the data the second it dropped, while the Street was still modeling MS alone. — Finaxus $ARGX $IBB
View on StockTwits ↗$ARGX Share Price: $879.28 Contract Selected: Nov 20, 2026 $880 Calls Buy Zone: $79.90 – $98.70 Target Zone: $131.75 – $161.02 Potential Upside: 56% ROI Time to Expiration: 163 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗$ARGX this one keeps refusing to break character.
View on StockTwits ↗$ARGX 👏🏼 LFG $HALO $SPCE $IBM Profits to VSEE 👀
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 20.5× sales vs its 20.0× historical median P/S.
Fair value ≈ $906.02 · price $924.52 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.